PMID- 33582674
OWN - NLM
STAT- MEDLINE
DCOM- 20210831
LR  - 20210831
IS  - 1421-9751 (Electronic)
IS  - 0008-6312 (Linking)
VI  - 146
IP  - 2
DP  - 2021
TI  - Proportion of Patients Eligible for Cardiac Contractility Modulation: Real-Life 
      Data from a Single-Center Heart Failure Clinic.
PG  - 195-200
LID - 10.1159/000512946 [doi]
AB  - INTRODUCTION: Based on recently published randomized controlled trials, cardiac 
      contractility modulation (CCM) seems to be an effective device-based therapeutic 
      option in symptomatic chronic heart failure (HF) (CHF). The aim of the current 
      study was to estimate what proportion of patients with CHF and left ventricular 
      ejection fraction (LVEF) <50% could be eligible for CCM based on the inclusion 
      criteria of the FIX-HF-5C trial. METHODS: Consecutive patients referred and 
      followed up at our HF clinic due to HF with reduced or mid-range LVEF were 
      retrospectively assessed. After a treatment optimization period of 3-6 months, 
      the inclusion criteria of the FIX-HF-5C trial (New York Heart Association (NYHA) 
      class III/IV, 25% </= LVEF </=45%, QRS <130 ms, and sinus rhythm) were applied to 
      determine the number of patients eligible for CCM. RESULTS: Of the 640 patients 
      who were involved, the proportion of highly symptomatic patients in NYHA class 
      III/IV decreased from 77.0% (n = 493) at baseline to 18.6% (n = 119) after the 
      treatment optimization period (p < 0.001). Mean LVEF increased significantly from 
      29.0 +/- 7.9% to 36.3 +/- 9.9% (p < 0.001), while the proportion of patients with 25% 
      </= LVEF </=45% increased from 69.7% (n = 446) to 73.3% (n = 469) (p < 0.001). QRS 
      duration was below 130 ms in 63.1% of patients, while 30.0% of patients had 
      persistent or permanent atrial fibrillation. We found that the eligibility 
      criteria for CCM therapy based on the FIX-HF-5C study were fulfilled for 23.0% (n 
      = 147) of patients at baseline and 5.2% (n = 33) after treatment optimization. 
      CONCLUSION: This single-center cohort study showed that 5% of patients with CHF 
      and impaired LVEF immediately after treatment optimization fulfilled the 
      inclusion criteria of the FIX-HF-5C study and would be candidates for CCM.
CI  - (c) 2021 S. Karger AG, Basel.
FAU - Pilecky, David
AU  - Pilecky D
AD  - Department of Cardiology, Medical Centre - Hungarian Defence Forces, Budapest, 
      Hungary, pileckyd@gmail.com.
AD  - Department of Internal Medicine III, Klinikum Passau, Passau, Germany, 
      pileckyd@gmail.com.
FAU - Muk, Balazs
AU  - Muk B
AD  - Department of Cardiology, Medical Centre - Hungarian Defence Forces, Budapest, 
      Hungary.
FAU - Majoros, Zsuzsanna
AU  - Majoros Z
AD  - Department of Cardiology, Medical Centre - Hungarian Defence Forces, Budapest, 
      Hungary.
FAU - Vagany, Denes
AU  - Vagany D
AD  - Department of Cardiology, Medical Centre - Hungarian Defence Forces, Budapest, 
      Hungary.
FAU - Kosa, Krisztina
AU  - Kosa K
AD  - Department of Cardiology, Medical Centre - Hungarian Defence Forces, Budapest, 
      Hungary.
FAU - Szabo, Marta
AU  - Szabo M
AD  - Department of Cardiology, Medical Centre - Hungarian Defence Forces, Budapest, 
      Hungary.
FAU - Szogi, Emese
AU  - Szogi E
AD  - Department of Cardiology, Medical Centre - Hungarian Defence Forces, Budapest, 
      Hungary.
FAU - Dekany, Miklos
AU  - Dekany M
AD  - Department of Cardiology, Medical Centre - Hungarian Defence Forces, Budapest, 
      Hungary.
FAU - Kiss, Robert Gabor
AU  - Kiss RG
AD  - Department of Cardiology, Medical Centre - Hungarian Defence Forces, Budapest, 
      Hungary.
FAU - Nyolczas, Noemi
AU  - Nyolczas N
AD  - Department of Cardiology, Medical Centre - Hungarian Defence Forces, Budapest, 
      Hungary.
AD  - Doctoral School of Clinical Medicine, University of Szeged, Szeged, Hungary.
LA  - eng
PT  - Journal Article
DEP - 20210212
PL  - Switzerland
TA  - Cardiology
JT  - Cardiology
JID - 1266406
SB  - IM
MH  - Cohort Studies
MH  - *Heart Failure/therapy
MH  - Humans
MH  - Retrospective Studies
MH  - Stroke Volume
MH  - Treatment Outcome
MH  - *Ventricular Function, Left
OTO - NOTNLM
OT  - Cardiac contractility modulation
OT  - Cardiac implantable electric device
OT  - Chronic heart failure
EDAT- 2021/02/15 06:00
MHDA- 2021/09/01 06:00
CRDT- 2021/02/14 20:36
PHST- 2020/07/22 00:00 [received]
PHST- 2020/10/15 00:00 [accepted]
PHST- 2021/02/15 06:00 [pubmed]
PHST- 2021/09/01 06:00 [medline]
PHST- 2021/02/14 20:36 [entrez]
AID - 000512946 [pii]
AID - 10.1159/000512946 [doi]
PST - ppublish
SO  - Cardiology. 2021;146(2):195-200. doi: 10.1159/000512946. Epub 2021 Feb 12.